FrancophonIA/ELRC3.0 huggingface dataset:
English: Dosing with liraglutide during mid-gestation caused a reduction in maternal weight and foetal growth with equivocal effects on ribs in rats and skeletal variation in the rabbit.
Croatian: Doziranje liraglutida tijekom sredine gestacijskog razdoblja uzrokovalo je smanjenje majčine težine i fetalnog rasta, uz dvosmislene učinke na rebra kod štakora te skeletne promjene u kunića.
English: Therapeutic experience in patients ≥75 years of age is limited and use in these patients is not recommended (see sections 4.4 and 5.2).
Croatian: ≥75 godina ograničeno je i ne preporučuje se primjena lijeka u tih bolesnika (vidjeti dijelove 4.4 i 5.2).
English: People with diabetes
Croatian: Osobe sa šećernom bolešću
English: Saxenda was evaluated for safety in 5 double-blind, placebo controlled trials that enrolled 5,813 obese patients or overweight patients with at least one weight-related comorbidity.
Croatian: Sigurnost lijeka Saxenda procijenjena je u 5 dvostruko slijepih, placebom kontroliranih ispitivanja koja su uključivala 5813 pretilih bolesnika ili bolesnika s prekomjernom tjelesnom težinom s najmanje jednim komorbiditetom povezanim s težinom.
English: Clinical trials suggest that liraglutide improves and sustains beta-cell function, according to HOMA-B and the proinsulin-to-insulin ratio.
Croatian: Klinička ispitivanja upućuju na to da liraglutid poboljšava i održava funkciju beta stanica prema procjeni modela homeostaze za funkciju beta stanica (HOMA-B), kao i omjer proinzulina i inzulina.
English: There are limited data from the use of liraglutide in pregnant women.
Croatian: Podaci o primjeni liraglutida u trudnica su ograničeni.
English: In trial 4, more patients maintained the weight loss achieved prior to treatment initiation with liraglutide than with placebo (81.4% and 48.9%, respectively).
Croatian: U 4. ispitivanju više je bolesnika održalo gubitak tjelesne težine ostvaren prije početka liječenja liraglutidom nego placebom (81,4% odnosno 48,9%).
English: Patients with type 2 diabetes mellitus receiving liraglutide in combination with insulin and/or sulfonylurea may have an increased risk of hypoglycaemia.
Croatian: U bolesnika sa šećernom bolešću tipa 2 koji primaju liraglutid u kombinaciji s inzulinom i/ili sulfonilurejom moguć je povećani rizik od hipoglikemije.
English: If you have liver problems, consult your doctor.
Croatian: Ako imate problema s jetrom, posavjetujte se sa svojim liječnikom.
English: It is not known whether liraglutide is excreted in human milk.
Croatian: Nije poznato izlučuje li se liraglutid u majčino mlijeko.
English: The effect on rate of gastric emptying was equivalent between liraglutide 1.8 mg and 3.0 mg, (paracetamol AUC0-300 min).
Croatian: Učinak na brzinu pražnjenja želuca bio je jednak kod 1,8 mg liraglutida i kod 3,0 mg liraglutida (paracetamol AUC0-300 min).
English: You can keep the pen for 1 month when stored at a temperature below 30°C or in a refrigerator (2°C to 8°C).
Croatian: Brizgalicu možete koristiti mjesec dana ako je čuvate na temperaturi ispod 30°C ili u hladnjaku (2°C do 8°C).
English: With continued treatment with liraglutide, 86.2% of these early responders are predicted to achieve a weight loss of ≥5% and 51% are predicted to achieve a weight loss of ≥10%
Croatian: Uz nastavak liječenja liraglutidom za 86,2% od tih ispitanika s ranim odgovorom na liječenje predviđa se da će postići smanjenje tjelesne težine od ≥5%, a za 51% predviđa se da će postići smanjenje tjelesne težine od ≥10% nakon jedne godine liječenja.
English: Dry mouth Dyspepsia Gastritis
Croatian: Suha usta Dispepsija Gastritis
English: In the 56-week part of trial 1, fewer patients treated with liraglutide had developed type 2 diabetes mellitus compared to patients treated with placebo (0.2% vs. 1.1%).
Croatian: U 56-tjednom dijelu 1. ispitivanja manje je bolesnika liječenih liraglutidom razvilo šećernu bolest tipa 2 u usporedbi s bolesnicima koji su primali placebo (0,2% naspram 1,1%).
English: The glucose-lowering effect is more pronounced in patients with pre-diabetes and diabetes compared to patients with normoglycaemia.
Croatian: Učinak snižavanja glukoze izraženiji je u bolesnika s predijabetesom i dijabetesom u usporedbi s bolesnicima s normoglikemijom.
English: BMI (Body Mass Index) is a measure of your weight in relation to your height.
Croatian: ITM (indeks tjelesne mase) je omjer Vaše težine i visine.
English: Flow check symbol selected
Croatian: Simbol za provjeru protoka odabran
English: It should be injected in the abdomen, thigh or upper arm.
Croatian: Injicira se u abdomen, bedro ili nadlakticu.
English: Please see section ‘Description of selected adverse reactions' for further information.
Croatian: Za dodatne informacije vidjeti dio „Opis izdvojenih nuspojava”.
English: Figure 3 Change from randomisation (week 0) in body weight (%) by time in trial 4
Croatian: Slika 3 Promjena od randomizacije (0. tjedan) u tjelesnoj težini (%) u odnosu na vrijeme u 4. ispitivanju
English: What Saxenda is used for
Croatian: Za što se Saxenda koristi
English: Consistent with the potentially immunogenic properties of protein and peptide pharmaceuticals, patients may develop anti-liraglutide antibodies following treatment with liraglutide.
Croatian: Sukladno mogućim imunogenim svojstvima lijekova koji sadrže proteine i peptide, u bolesnika se tijekom liječenja liraglutidom mogu razviti protutijela na liraglutid.
English: especially children.
Croatian: I DOHVATA DJECE
English: In the 160-week part of trial 1, the primary efficacy endpoint was the proportion of patients with onset of type 2 diabetes mellitus evaluated as time to onset.
Croatian: U 160-tjednom dijelu 1. ispitivanja, primarna mjera ishoda djelotvornosti bila je udio bolesnika s nastupom šećerne bolesti tipa 2 procijenjena kao vrijeme do nastupa.
English: The change in heart rate was reversible upon discontinuation of liraglutide (see section 4.4).
Croatian: Promjena srčane frekvencije bila je reverzibilna nakon prekida liječenja liraglutidom (vidjeti dio 4.4).
English: Saxenda is not recommended for use in patients with severe renal impairment (creatinine clearance <30 ml/min) including patients with end-stage renal disease (see sections 4.4, 4.8 and 5.2).
Croatian: Primjena lijeka Saxenda ne preporučuje se u bolesnika s teškim oštećenjem bubrega (klirens kreatinina ≤30 ml/min), uključujući bolesnike sa završnim stadijem bubrežne bolesti (vidjeti dijelove 4.4, 4.8 i 5.2).
English: The exposure of liraglutide decreases with an increase in baseline body weight.
Croatian: Izloženost liraglutidu smanjuje se kako se povećava početna vrijednost tjelesne težine.
English: In this trial, documented symptomatic hypoglycaemia (defined as plasma glucose ≤3.9 mmol/L accompanied by symptoms) was reported by 47.2% of patients treated with liraglutide 3.0 mg/day and by 51.8% of patients treated with placebo.
Croatian: U ovom ispitivanju, dokumentiranu simptomatsku hipoglikemiju (definirana kao vrijednost glukoze u plazmi ≤3,9 mmol/l koja je popraćena simptomima) prijavilo je 47,2% bolesnika liječenih liraglutidom 3,0 mg/dan i 51,8% bolesnika koji su primali placebo.
English: • Do not use Saxenda in combination with other medicines that contain GLP-1 receptor agonists
Croatian: • Nemojte primjenjivati lijek Saxenda zajedno s drugim lijekovima koji sadrže agoniste receptora
English: Injection site reactions have been reported in patients treated with Saxenda.
Croatian: Reakcije na mjestu injiciranja prijavljene su u bolesnika liječenih lijekom Saxenda.
English: • Problems affecting the stomach and intestines, such as indigestion (dyspepsia), inflammation in the lining of the stomach (gastritis), stomach discomfort, upper stomach pain, heartburn, feeling bloated, wind (flatulence), belching and dry mouth
Croatian: • Problemi povezani sa želucem i crijevima kao što su probavne tegobe (dispepsija), upala sluznice želuca (gastritis), nelagoda u trbuhu, bol u gornjem dijelu trbuha, žgaravica, nadutost,
English: The pen is designed to be used with NovoFine or NovoTwist disposable needles
Croatian: Brizgalica je namijenjena uporabi s jednokratnim iglama NovoFine ili NovoTwist.
English: Saxenda is used for weight loss in addition to diet and exercise in adults aged 18 and above who have
Croatian: Saxenda se koristi za smanjenje tjelesne težine kao dodatak dijeti i tjelovježbi u odraslih osoba u dobi od 18 ili više godina koje imaju:
English: Based on the exposure response data, no dose adjustment is necessary based on gender.
Croatian: Na temelju podataka o odgovoru na izloženost nije potrebno prilagođavanje doze prema spolu.
English: Liraglutide stimulates insulin secretion and lowers glucagon secretion in a glucose-dependent manner which results in a lowering of fasting and post-prandial glucose.
Croatian: Liraglutid stimulira lučenje inzulina i snižava lučenje glukagona u ovisnosti od glukoze, što rezultira snižavanjem glukoze natašte i glukoze nakon obroka.
English: Mean baseline HbA1c was 8.7 and had improved after 3 years by 1.2 % in patients assigned to liraglutide and by 0.8 % in patients assigned to placebo.
Croatian: Početna srednja vrijednost HbA1c iznosila je 8,7 i poboljšana je nakon 3 godine za 1,2% u bolesnika koji su primali liraglutid odnosno za 0,8% u bolesnika koji su primali placebo.
English: Two minor plasma metabolites were detected (≤9% and ≤5% of total plasma radioactivity exposure).
Croatian: Otkrivena su dva sporedna metabolita u plazmi (≤9% i ≤5%
English: No dose adjustment is required for patients with mild or moderate renal impairment (creatinine clearance ≥30 ml/min).
Croatian: Nije potrebno prilagođavanje doze u bolesnika s blagim ili umjerenim oštećenjem bubrega (klirens kreatinina ≥30 ml/min).
English: Disodium phosphate dihydrate Propylene glycol
Croatian: Natrijev hidrogenfosfat dihidrat Propilenglikol
English: Loss of fluid and dehydration
Croatian: Gubitak tekućine i dehidracija
English: If you forget to use Saxenda
Croatian: Ako ste zaboravili primijeniti lijek Saxenda
English: Saxenda is a weight loss medicine that contains the active substance liraglutide.
Croatian: Saxenda je lijek za smanjenje tjelesne težine koji sadrži djelatnu tvar liraglutid.
English: Blood glucose self-monitoring is necessary to adjust the dose of insulin or insulin-secretagogues (see section
Croatian: Nužna je samokontrola razine glukoze u krvi radi prilagođavanja doze inzulina ili inzulinskih sekretagoga (vidjeti dio 4.4).
English: Substances added to Saxenda may cause degradation of liraglutide.
Croatian: Tvari dodane lijeku Saxenda mogu izazvati razgradnju liraglutida.
English: Major adverse cardiovascular events (MACE) were adjudicated by an external independent group of experts and defined as non-fatal myocardial infarction, non-fatal stroke and cardiovascular death.
Croatian: Velike štetne kardiovaskularne događaje (engl. major adverse cardiovascular events, MACE) utvrdila je vanjska neovisna skupina stručnjaka i definirani su kao infarkt miokarda bez smrtnog ishoda,
English: - The active substance is liraglutide.
Croatian: - Djelatna tvar je liraglutid.
English: Among patients not concomitantly treated with sulfonylurea, 15.7% of patients treated with Saxenda and 7.6% of patients treated with placebo reported documented symptomatic hypoglycaemic events (defined as plasma glucose ≤3.9 mmol/L accompanied by symptoms).
Croatian: Od bolesnika koji nisu istodobno liječeni sulfonilurejom, 15,7% bolesnika liječenih lijekom Saxenda i 7,6% bolesnika koji su primali placebo prijavilo je dokumentirane simptomatske hipoglikemijske događaje (koji se definiraju kao vrijednost glukoze u plazmi ≤3,9 mmol/l koja je popraćena simptomima).
English: A Approx. how much solution is left
Croatian: Otprilike koliko je otopine preostalo
English: The average liraglutide steady state concentration (AUCτ/24) reached approximately 31 nmol/L in obese (BMI 30-40 kg/m2) patients following administration of 3 mg liraglutide.
Croatian: Prosječna koncentracija liraglutida (AUCτ/24) u stanju dinamičke ravnoteže dostigla je otprilike 31 nmol/l u pretililh (ITM 30-40 kg/m2) bolesnika nakon primjene 3 mg liraglutida.
English: Liraglutide did not reduce the plaque size of already established plaques.
Croatian: Liraglutid nije smanjio veličinu plaka već formiranih plakova.
English: After first use: Store below 30°C or store in a refrigerator (2°C-8°C).
Croatian: Nakon prve primjene: čuvati na temperaturi ispod 30°C ili čuvati u hladnjaku (2°C-8°C).
English: • a BMI of 30 kg/m² or greater (obese) or
Croatian: • indeks tjelesne mase (ITM) 30 kg/m² ili veći (pretili) ili
English: The pen can dial up to a maximum of 3.0 mg.
Croatian: Brizgalicom možete odmjeriti najviše 3,0 mg.
English: Also, in these patients documented symptomatic hypoglycaemia was reported by 43.6% of patients treated with Saxenda and in 27.3% of patients treated with placebo.
Croatian: Također, u tih bolesnika dokumentiranu simptomatsku hipoglikemiju prijavilo je 43,6% bolesnika liječenih lijekom Saxenda i 27,3% bolesnika koji su primali placebo.
English: Increased amylase *Hypoglycaemia (based on self-reported symptoms by patients and not confirmed by blood glucose measurements) reported in patients without type 2 diabetes mellitus treated with Saxenda in combination with diet and exercise.
Croatian: Povišena amilaza *Hipoglikemija (na temelju simptoma koje su prijavili bolesnici i koja nije potvrđena mjerenjima glukoze u krvi) prijavljena je u bolesnika koji ne boluju od šećerne bolesti tipa 2, a koji su liječeni lijekom Saxenda u kombinaciji s dijetom i tjelovježbom.
English: Talk to your doctor if you have palpitations (you feel aware of your heartbeat) or if you have feelings of a racing heartbeat while at rest during Saxenda treatment.
Croatian: Obratite se svom liječniku ako tijekom liječenja lijekom Saxenda imate palpitacije (osjećaj lupanja srca) ili osjećate ubrzane otkucaje srca dok mirujete.
English: More patients with pre-diabetes at baseline had reversed their prediabetes compared to patients treated with placebo (69.2% vs. 32.7%).
Croatian: Više je bolesnika s predijabetesom na početku ispitivanja postiglo reverziju predijabetesa u usporedbi s bolesnicima koji su primali placebo (69,2% naspram 32,7%).
English: Among patients concomitantly treated with sulfonylurea, 60.9% of patients treated with liraglutide 3.0 mg/day and 60.0% of patients treated with placebo reported documented symptomatic hypoglycaemic events.
Croatian: Od bolesnika koji su istodobno liječeni sulfonilurejom, 60,9% bolesnika liječenih liraglutidom 3,0 mg/dan i 60% bolesnika koji su primali placebo prijavilo je dokumentirane simptomatske hipoglikemijske događaje.
English: Neonatal growth was reduced in rats while exposed to liraglutide and persisted in the post-weaning period in the high dose group.
Croatian: Neonatalni rast bio je smanjen u štakora tijekom izloženosti liraglutidu i to se zadržalo tijekom razdoblja nakon odvikavanja od sisanja u skupini na visokoj dozi lijeka.
English: For the proportions of patients losing ≥5/>10% body weight, estimated odds ratios are presented.
Croatian: Kao udjeli bolesnika koji su izgubili ≥5/>10% tjelesne težine navedeni su procijenjeni omjeri izgleda.
English: The 160-week part of trial 1 assessed time to onset of type 2 diabetes in the 2,254 randomised patients with pre-diabetes (1,128 completers).
Croatian: U 160-tjednom dijelu 1. ispitivanja procijenjeno je vrijeme do nastupa šećerne bolesti tipa 2 u 2254 randomiziranih bolesnika s predijabetesom (od kojih je 1128 završilo ispitivanje).
English: Liraglutide exposure was reduced in patients with renal impairment compared to individuals with normal renal function in a single-dose trial (0.75 mg).
Croatian: Izloženost liraglutidu bila je smanjena u bolesnika s oštećenjem bubrega u usporedbi s pojedincima s normalnom bubrežnom funkcijom u ispitivanju s jednom dozom lijeka (0,75 mg).
English: • Trial 2 (SCALE Diabetes - 1922): A 56-week trial assessing body weight loss in 846 randomised (628 completers) obese and overweight patients with insufficiently controlled type 2 diabetes mellitus (HbA1c range 7-10%).
Croatian: • 2. ispitivanje (SCALE Diabetes - 1922): 56-tjedno ispitivanje koje je procjenjivalo gubitak tjelesne težine kod 846 randomiziranih (od kojih je 628 dovršilo ispitivanje) pretilih i bolesnika s prekomjernom tjelesnom težinom s nedovoljno kontroliranom šećernom bolešću tipa 2 (raspon HbA1c 7-10%).
English: No dose adjustment is recommended for patients with mild or moderate hepatic impairment.
Croatian: Ne preporučuje se prilagođavanje doze u bolesnika s blagim ili umjerenim oštećenjem jetre.
English: In rats, a no observed adverse effect level (NOAEL) was not observed.
Croatian: Najveća doza bez štetnog učinka (engl. no observed adverse effect level, NOAEL) u štakora nije zabilježena.
English: Waist circumference, cm
Croatian: Opseg struka, cm
English: • Feeling sick (nausea), being sick (vomiting), diarrhoea, constipation - these usually go away after a few days or weeks.
Croatian: Vrlo često: mogu se javiti u više od 1 na 10 osoba • Mučnina, povraćanje, proljev, zatvor - ove nuspojave obično nestaju nakon nekoliko dana ili tjedana.
English: The warning signs of low blood sugar may come on suddenly and can include: cold sweat, cool pale skin, headache, fast heartbeat, feeling sick,
Croatian: Znakovi koji upozoravaju na nisku razinu šećera u krvi mogu se pojaviti iznenada, a mogu uključivati: hladan znoj, hladnu blijedu kožu, glavobolju, ubrzane otkucaje srca, mučninu, snažan osjećaj gladi, promjene vida, osjećaj pospanosti, osjećaj slabosti, nervozu, tjeskobu, smetenost, poteškoće s koncentracijom te tresavicu (nevoljno drhtanje).
English: Dose counter stopped:
Croatian: Primjer Brojčanik doze zaustavljen: preostalo
English: Your doctor may adjust the dose of your diabetes medicines to prevent you from getting low blood sugar.
Croatian: Vaš liječnik Vam može prilagoditi doze lijekova za šećernu bolest kako bi se spriječila niska razina šećera u krvi.
English: Patients with heart failure
Croatian: Bolesnici sa srčanim zatajenjem
English: - The other ingredients are disodium phosphate dihydrate, propylene glycol, phenol, hydrochloric acid and sodium hydroxide (for pH adjustment) and water for injections.
Croatian: Drugi sastojci su natrijev hidrogenfosfat dihidrat, propilenglikol, fenol, kloridna kiselina i natrijev hidroksid (za podešavanje pH) te voda za injekcije.
English: The pharmacokinetics of liraglutide was evaluated in patients with varying degree of hepatic impairment in a single-dose trial (0.75 mg).
Croatian: Farmakokinetika liraglutida procjenjivala se u bolesnika s različitim stupnjevima oštećenja jetre u ispitivanju s jednom dozom lijeka (0,75 mg).
English: In clinical trials for weight management, a higher rate of cholelithiasis and cholecystitis was observed in patients treated with liraglutide than in patients on placebo.
Croatian: U kliničkim ispitivanjima za kontrolu tjelesne težine zabilježena je viša stopa kolelitijaze i kolecistitisa kod bolesnika liječenih liraglutidom nego u bolesnika koji su dobivali placebo.
English: Your doctor may adjust the dose of your diabetes medicine to prevent you from getting low blood sugar.
Croatian: Vaš liječnik Vam može prilagoditi dozu lijeka za šećernu bolest kako bi se spriječila niska razina šećera u krvi.
English: In all the long-term clinical trials with Saxenda, there were 6 MACE for patients treated with liraglutide and 10 MACE for placebo-treated patients.
Croatian: U svim dugotrajnim kliničkim ispitivanjima lijeka Saxenda dogodilo se 6 MACE-a u bolesnika liječenih liraglutidom i 10 MACE-a u bolesnika koji su primali placebo.
English: EXP Discard pen 1 month after first use
Croatian: EXP Mjesec dana nakon prve primjene brizgalicu baciti u otpad.
English: Liraglutide does not increase energy expenditure compared to placebo.
Croatian: U usporedbi s placebom liraglutid ne povećava potrošnju energije.
English: • ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.
Croatian: • ≥30 kg/m² (pretili), ili • ≥27 kg/m² do <30 kg/m² (prekomjerna tjelesna težina) uz prisutnost najmanje jednog komorbiditeta povezanog s tjelesnom težinom kao što je disglikemija (predijabetes ili šećerna bolest tipa 2), hipertenzija, dislipidemija ili opstruktivna apneja u snu.
English: There is little experience with this medicine in patients with liver problems.
Croatian: Malo je iskustva s primjenom ovog lijeka u bolesnika koji imaju probleme s jetrom.
English: Treatment with liraglutide significantly reduced the severity of obstructive sleep apnoea as assessed by change from baseline in the AHI compared with placebo (table 6).
Croatian: Liječenje liraglutidom značajno je smanjilo težinu opstruktivne apneje u snu prema procjeni promjene od početne vrijednosti u AHI-ju u usporedbi s placebom (tablica 6).
English: This is more likely to occur at the start of treatment and may be due to being sick (vomiting), feeling sick (nausea) and diarrhoea
Croatian: Veća je vjerojatnost da će do toga doći na početku liječenja i može biti uzrokovano povraćanjem, mučninom i proljevom
English: • Trial 3 (SCALE Sleep Apnoea - 3970): A 32-week trial assessing sleep apnoea severity and body weight loss in 359 randomised (276 completers) obese patients with moderate or severe obstructive sleep apnoea.
Croatian: • 3. ispitivanje (SCALE Sleep Apnoea - 3970): 32-tjedno ispitivanje koje je procjenjivalo težinu apneje u snu i gubitak tjelesne težine kod 359 randomiziranih (od kojih je 276 dovršilo ispitivanje) pretilih bolesnika s umjerenom ili teškom opstruktivnom apnejom u snu.
English: Lisinopril median tmax was delayed from 6 h to 8 h with liraglutide.
Croatian: Uz liraglutid medijan tmax lizinoprila bio je odgođen sa 6 h na 8 h.
English: In clinical trials, tachycardia was reported in 0.6% of patients treated with Saxenda and in 0.1% of patients treated with placebo.
Croatian: U kliničkim ispitivanjima tahikardija je prijavljena u 0,6% bolesnika liječenih lijekom Saxenda i u 0,1% bolesnika koji su primali placebo.
English: As liraglutide for weight management was not investigated in subjects with mild or moderate hepatic impairment, it should be used with caution in these patients (see sections 4.2 and 5.2).
Croatian: Budući da liraglutid nije ispitivan za kontrolu tjelesne težine u ispitanika s blagim ili umjerenim oštećenjem jetre, potrebno ga je primjenjivati s oprezom u tih bolesnika (vidjeti dijelove 4.2 i 5.2).
English: Always dispose of the needle after each injection to ensure convenient injections and prevent blocked needles.
Croatian: Nakon svakog injiciranja uvijek bacite iglu u otpad kako biste osigurali pogodno injiciranje i kako biste spriječili začepljenje igala.
English: • Changed sense of taste
Croatian: • Promijenjen osjet okusa • Omaglica
English: Full Analysis Set.
Croatian: Potpuni skup podataka za analizu.
English: Your pen is designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm and as thin as 32 G.
Croatian: Brizgalica je namijenjena uporabi s jednokratnim iglama NovoFine ili NovoTwist duljine do 8 mm i ne tanjim od 32 G.
English: An increase in heart rate was observed with liraglutide in clinical trials (see section 5.1).
Croatian: U kliničkim ispitivanjima zabilježen je porast srčane frekvencije prilikom primjene liraglutida (vidjeti dio 5.1).
English: • Always keep your pen and needles out of sight and reach of others,
Croatian: Dodatne važne informacije • Brizgalicu i igle uvijek čuvajte izvan pogleda i dohvata drugih, osobito djece.
English: The patient should be observed for clinical signs of dehydration and blood glucose should be monitored.
Croatian: Potrebno je pratiti kliničke znakove dehidracije te pratiti glukozu u krvi bolesnika.
English: There is no clinical experience in patients with congestive heart failure New York Heart Association (NYHA) class IV, and liraglutide is therefore not recommended for use in these patients.
Croatian: New York Heart Association) klasifikaciji pa se stoga primjena liraglutida ne preporučuje u tih bolesnika.
English: tmax was delayed by 1.5 h with liraglutide for both compounds.
Croatian: Uz liraglutid tmax je odgođen za 1,5 h za oba spoja.